ライフサイエンスコーパス: allopurinol

1 purinol; P=0.23 for 120 mg of febuxostat vs. allopurinol).

2 purinol; P=0.16 for 120 mg of febuxostat vs. allopurinol).

3 d with the xanthine oxidoreductase inhibitor allopurinol.

4 ylephrine (PE) following maternal vehicle or allopurinol.

5 (DeltaG( approximately ATP)) increased with allopurinol.

6 oxidative stress was completely abolished by allopurinol.

7 sburicase plus allopurinol, and 27 hours for allopurinol.

8 ontrol of plasma uric acid more rapidly than allopurinol.

9 ase, 92 rasburicase plus allopurinol, and 91 allopurinol.

10 gle agent and in sequential combination with allopurinol.

11 eath or serious adverse events compared with allopurinol.

12 h rasburicase plus allopurinol, and 66% with allopurinol.

13 were more frequent with febuxostat than with allopurinol.

14 FN-alpha transcription was inhibited only by allopurinol.

15 elate to delayed or insufficient dosing with allopurinol.

16 tly by the xanthine oxidoreductase inhibitor allopurinol.

17 not the xanthine/xanthine oxidase inhibitor, allopurinol.

18 not by the xanthine oxidoreductase inhibitor allopurinol.

19 ruct a dose-response curve for the effect of allopurinol.

20 tenuated by inhibiting xanthine oxidase with allopurinol.

21 n a manner reversible by XOR inhibition with allopurinol.

22 thyl ester or the xanthine oxidase inhibitor allopurinol.

23 smokers and controls and were not altered by allopurinol.

24 stance vessels is rapidly reversed with oral allopurinol.

25 rette smokers by administering the inhibitor allopurinol.

26 ovascular safety of febuxostat compared with allopurinol.

27 nistration of the xanthine oxidase inhibitor allopurinol.

28 hyperuricemic rats, which was ameliorated by allopurinol.

29 ge, were actually reduced in the presence of allopurinol.

30 t compared with those treated with 100 mg of allopurinol (0 [0%] of 10).

31 +1.3 +/- 7.22 mls; p = 0.047), improved FMD (allopurinol +0.82 +/- 1.8% vs. placebo -0.69 +/- 2.8%; p

32 Rash occurred more frequently with allopurinol (10% versus 2%, P=0.01), but there was no di

33 romol/L) and attenuated by the XOR inhibitor allopurinol (100 micromol/L) in acidic and hypoxic condi

34 urface area in the preceding year to receive allopurinol (100 to 300 mg daily) or placebo.

35 d patients were randomly assigned to receive allopurinol (185 patients) or placebo (184 patients).

36 gmentation index improved significantly with allopurinol (2.6 +/- 7.0%, p < 0.001) but not with place

37 +/- 4.48 g; p = 0.007) and LVM index (LVMI) (allopurinol -2.2 +/- 2.78 g/m(2) vs. placebo -0.53 +/- 2

38 +/- 2.8%; p = 0.017) and augmentation index (allopurinol -2.8 +/- 5.1% vs. placebo +0.9 +/- 7%; p = 0

39 purinol also reduced LV end-systolic volume (allopurinol -2.81 +/- 7.8 mls vs. placebo +1.3 +/- 7.22

40 Allopurinol, 200 mg twice daily for 4 weeks, and placebo

41 serum urate levels <6.0 mg/dl compared with allopurinol (22%) and placebo (0%).

42 per 100 patient-years]) was non-inferior to allopurinol (241 patients [2.05 events per 100 patient-y

43 response to acetylcholine compared with both allopurinol 300 mg/d and placebo (% change in forearm bl

44 se 0.20 mg/kg/d days 1 to 3 followed by oral allopurinol 300 mg/d days 3 to 5), or allopurinol (300 m

45 cardiomyopathy in a double-blind fashion to allopurinol (300 mg intravenously) or placebo infusion,

46 ceive either febuxostat (80 mg or 120 mg) or allopurinol (300 mg) once daily for 52 weeks; 760 receiv

47 y oral allopurinol 300 mg/d days 3 to 5), or allopurinol (300 mg/d orally days 1 to 5).

48 by 160 mg weekly) or placebo, and started on allopurinol (300 mg/day, titrated to serum urate <6 mg/d

49 ained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with

50 daily febuxostat (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or

51 cebo, allopurinol significantly reduced LVM (allopurinol -5.2 +/- 5.8 g vs. placebo -1.3 +/- 4.48 g;

52 ents of STZ-rats with the hypouricemic drugs allopurinol (50 mg/kg) and benzbromarone (10 mg/kg) give

53 Allopurinol 600 mg/d significantly increased forearm blo

54 enerated randomisation to assign patients to allopurinol (600 mg per day) or placebo for 6 weeks befo

55 conducted in 80 patients with CAD, comparing allopurinol (600 mg/day) with placebo.

56 -III chronic heart failure, comparing 300 mg allopurinol, 600 mg allopurinol, and placebo for the fir

57 Allopurinol, 600 mg/day, or placebo was given over the s

58 reatment with an xanthine oxidase inhibitor (allopurinol), a Na(+)/H(+) exchange blocker (amiloride),

59 Acute administration of allopurinol, a competitive inhibitor of XO, reduced plas

60 port the first OHCU decarboxylase inhibitor, allopurinol, a structural isomer of hypoxanthine.

61 sed females to blood meals supplemented with allopurinol, a well-characterized XDH inhibitor.

62 Allopurinol, a xanthine oxidase inhibitor, attenuated en

63 Allopurinol, a xanthine oxidase inhibitor, blocks purine

64 Allopurinol, a xanthine oxidase inhibitor, can reverse t

65 Allopurinol, a xanthine oxidase inhibitor, has been show

66 Allopurinol, a xanthine oxidase inhibitor, prolongs the

67 Allopurinol, a xanthine oxidoreductase (XOR) inhibitor,

68 travenous administration of the XO inhibitor allopurinol acutely improves the relative and absolute c

69 The present study determines the effect of allopurinol administration prior to hypoxia on brain lev

70 00-120 ms) before and after the XO inhibitor allopurinol (ALLO, 50 micromol/L).

71 ricase followed by oral allopurinol and with allopurinol alone in controlling plasma uric acid.

72 Allopurinol (ALP) hypersensitivity is a major cause of s

73 Apocynin and allopurinol also decreased V(2)O(5)-induced IFN-beta mRN

74 We sought to ascertain whether allopurinol also improves endothelial dysfunction in opt

75 potassium supplementation and treatment with allopurinol also increase urinary nitric oxide excretion

76 Allopurinol also reduced LV end-systolic volume (allopur

77 A and malR, with addition of trimethoprim or allopurinol also resulting in an equivalent intracellula

78 We conclude that maternal treatment with allopurinol alters in vivo maternal, umbilical and fetal

79 Allopurinol ameliorates endothelial dysfunction and arte

80 Allopurinol, an inhibitor of xanthine oxidoreductase (XO

81 .0 ml per minute per 1.73 m(2) per year with allopurinol and -2.5 ml per minute per 1.73 m(2) per yea

82 tal of 267 patients were assigned to receive allopurinol and 263 to receive placebo.

83 atment period, 31 patients were allocated to allopurinol and 28 were analysed, and 34 were allocated

84 Patients received allopurinol and aspirin for prophylaxis.

85 me activation in cells by treating mice with allopurinol and discovered that allopurinol treatment co

86 Studies of allopurinol and febuxostat lowering of serum urate have

87 Nevertheless, both allopurinol and febuxostat treatment has sustained the h

88 safety of the approved urate-lowering drugs, allopurinol and febuxostat.

89 Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare c

90 tors and the xanthine oxidase (XO) inhibitor allopurinol and in NOS-3 knockout (KO) mice.

91 ep dose-response relationship exists between allopurinol and its effect on endothelial function.

92 point estimate (absolute difference between allopurinol and placebo) was 43 s (95% CI 31-58).

93 wn that the use of uric acid-lowering agents allopurinol and probenecid can lower blood pressure in a

94 ently available urate-lowering drugs include allopurinol and probenecid.

95 reased from 6.1 to 3.9 mg per deciliter with allopurinol and remained at 6.1 mg per deciliter with pl

96 Specific inhibition of XOD by allopurinol and sodium tungstate led to an increase in i

97 case alone with rasburicase followed by oral allopurinol and with allopurinol alone in controlling pl

98 or rasburicase, 4 hours for rasburicase plus allopurinol, and 27 hours for allopurinol.

99 with rasburicase, 78% with rasburicase plus allopurinol, and 66% with allopurinol.

100 ts received rasburicase, 92 rasburicase plus allopurinol, and 91 allopurinol.

101 ts were 60 years or older, already receiving allopurinol, and had at least one additional cardiovascu

102 ailure, comparing 300 mg allopurinol, 600 mg allopurinol, and placebo for the first study and 1000 mg

103 GdCl(3), the xanthine oxidase (XO) inhibitor allopurinol, and the Fe(III) chelator Desferal resulted

104 ated the uptake of the anti-leishmanial drug allopurinol, and the nt3((-/-)) mutants were resistant t

105 mass index, use of diuretics, beta-blockers, allopurinol, and uricosuric agents, self-reported hypert

106 nt difference in clinical status between the allopurinol- and placebo-treated patients (worsened 45%

107 Allopurinol (AP) is administered in UA lowering therapy.

108 ions to be used alone or in combination with allopurinol are undergoing rigorous evaluation to use fo

109 Febuxostat and allopurinol are urate-lowering therapies used to treat p

110 ors and for the coadministration of 6-TG and allopurinol as an immunomodulation strategy in inflammat

111 and the practical application of the use of allopurinol as monotherapy for this condition.

112 In participants without diabetes mellitus, allopurinol associated with a trend toward improved flow

113 We randomly assigned 67 subjects to allopurinol at 300 mg/d or placebo for 9 months; 53 pati

114 of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300

115 previous cardiovascular events) to continue allopurinol (at the optimised dose) or start febuxostat

116 Allopurinol attenuated both the increase in A1AR express

117 reatment with the xanthine oxidase inhibitor allopurinol being considered in human complicated pregna

118 thout following immunomodulation (thiopurine-allopurinol, biologicals, methotrexate, tacrolimus) and

119 Amiloride, and to a lesser extent allopurinol but not vitamin E, significantly decreased l

120 the *NO end products were not suppressed by allopurinol but were by aminoguanidine.

121 treated with the xanthine oxidase inhibitor allopurinol, but the duration of patent parasitemia was

122 Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated g

123 This study demonstrates that allopurinol can regress left ventricular mass and improv

124 study sought to ascertain whether high-dose allopurinol causes regression of left ventricular mass (

125 We therefore investigated whether allopurinol causes regression of LVH in patients with T2

126 Allopurinol causes regression of LVM in patients with T2

127 onset mutation or between normal or abnormal allopurinol challenge and neuropsychological outcome.

128 gth evidence showed that neither citrate nor allopurinol combined with thiazide was superior to thiaz

129 choline coinfusion data showed that 600 mg/d allopurinol completely abolished the oxidative stress th

130 The mechanism of the anti-ischemic effect of allopurinol could be related to its reducing xanthine ox

131 e by inhibiting xanthine oxidoreductase with allopurinol could improve the proinflammatory endocrine

132 buxostat daily, 0.80 success rate; 300 mg of allopurinol daily, 0.39 success rate) and dose escalatio

133 ostat daily, 0.82 success rate; </=800 mg of allopurinol daily, 0.78 success rate).

134 Although blocking uric acid formation by allopurinol did not affect outcomes, administration of u

135 f progression, urate-lowering treatment with allopurinol did not slow the decline in eGFR as compared

136 idence-based QIs for gout management: QI 1 = allopurinol dose <300 mg in gout patients with renal ins

137 After a lead-in phase in which allopurinol dose was optimised towards achieving a serum

138 rtant to evaluate and document the safety of allopurinol during pregnancy, as it is finding new roles

139 In conclusion, allopurinol effectively and safely lowered serum uric ac

140 Since allopurinol elicits a similar increase in malR/malA expr

141 cid levels, xanthine oxidase inhibition with allopurinol failed to improve clinical status, exercise

142 Dose-escalation allopurinol-febuxostat sequential therapy is cost-effect

143 effectiveness ratios of dose escalation with allopurinol-febuxostat sequential therapy remained lower

144 Dose-escalation allopurinol-febuxostat sequential therapy was more costl

145 nt; allopurinol- or febuxostat-only therapy; allopurinol-febuxostat sequential therapy; and febuxosta

146 double-blinded manner to receive placebo or allopurinol for 12 weeks.

147 thine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout.

148 um stones, addition of thiazide, citrate, or allopurinol further reduced risk.

149 n the high-dose febuxostat group than in the allopurinol group (P=0.003) or the low-dose febuxostat g

150 was 68.7 ml per minute per 1.73 m(2) in the allopurinol group and 67.3 ml per minute per 1.73 m(2) i

151 reported in 84 of 182 patients (46%) in the allopurinol group and in 79 of 181 patients (44%) in the

152 GFR did not differ significantly between the allopurinol group and the placebo group (-3.33 ml per mi

153 ol was restored to near-normal levels in the allopurinol group but was attenuated in untreated mice.

154 percent) and none of the 253 patients in the allopurinol group died; all deaths were from causes that

155 n the febuxostat group and 169 (5.5%) in the allopurinol group withdrew from all follow-up.

156 tween the combined febuxostat groups and the allopurinol group).

157 comparison of each febuxostat group with the allopurinol group).

158 In the allopurinol group, 263 (8.6%) of 3065 patients died and

159 xostat group and 503 (16.5%) patients in the allopurinol group.

160 The placebo and the allopurinol groups had baseline serum uric acid levels (

161 reatment with the xanthine oxidase inhibitor allopurinol had no effect.

162 has been implicated in LVH development, and allopurinol has been previously shown to reduce vascular

163 The use of allopurinol has been shown to be associated with reduced

164 Allopurinol has been shown to improve endothelial functi

165 1 allele substantially increases the risk of allopurinol hypersensitivity, it is not an absolute requ

166 Maternal allopurinol impaired fetal alpha1-adrenergic pressor and

167 ation of the xanthine oxidase (XO) inhibitor allopurinol improves cardiac high-energy phosphate conce

168 whether lowering serum uric acid levels with allopurinol improves endothelial dysfunction in 80 parti

169 The hazard ratio (HR) for febuxostat versus allopurinol in a Cox proportional hazards model (adjuste

170 utic potential of xanthine oxidase inhibitor allopurinol in angina; ISRCTN15253766).

171 S might underpin the anti-ischemic effect of allopurinol in CAD.

172 The evidence suggests that the use of allopurinol in clinical practice should be approached wi

173 acid levels were significantly reduced with allopurinol in comparison with placebo (treatment differ

174 (Intravenous Allopurinol in Heart Failure; NCT00181155).

175 (Allopurinol in Patients with Diabetes and LVH; UKCRN 876

176 , non-inferiority trial of febuxostat versus allopurinol in patients with gout in the UK, Denmark, an

177 We report three cases of safe use of allopurinol in pregnancy for women with inflammatory bow

178 The safety of allopurinol in pregnancy is not known however.

179 bitor, represents a potential alternative to allopurinol in refractory gout patients.

180 Allopurinol increased median total exercise time to 393

181 Allopurinol increased the median time to ST depression t

182 Allopurinol increased the time to chest pain from a base

183 in was also suppressed by aminoguanidine and allopurinol independently.

184 oxidase by apocynin and xanthine oxidase by allopurinol individually reduced STAT-1 phosphorylation.

185 Maternal treatment with allopurinol induced maternal hypotension, tachycardia an

186 ss increases left ventricular afterload, any allopurinol-induced improvement in arterial compliance m

187 Allopurinol infusion increased mean cardiac PCr/ATP and

188 Allopurinol inhibited the increase in fetal plasma uric

189 Allopurinol inhibits purine degradation under severe hyp

190 da, and Mexico in patients with severe gout, allopurinol intolerance or refractoriness, and serum uri

191 ic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pe

192 Allopurinol is a frequently prescribed drug.

193 in the context of obstetric trials in which allopurinol is being administered to pregnant women when

194 otential for pregnant women to be exposed to allopurinol is increasing.

195 ards more toxic and less desirable pathways, allopurinol is proving to be an effective add on therapy

196 Allopurinol is the first-line urate-lowering therapy and

197 Introducing the xanthine oxidase inhibitor allopurinol led to rapid normalization of alanine aminot

198 Maternal allopurinol led to significant increases in fetal heart

199 ion of xanthine dehydrogenase by addition of allopurinol led to similar upregulation of malA and malR

200 of improvement in endothelial function with allopurinol lies in its ability to reduce vascular oxida

201 Compared with placebo, allopurinol lowered serum uric acid significantly but di

202 Overall, allopurinol lowered urate levels but did not exacerbate

203 Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filt

204 This raises the possibility that allopurinol might reduce future cardiovascular events an

205 tion) increase the likelihood that high-dose allopurinol might reduce future cardiovascular mortality

206 ors, serotonin-specific reuptake inhibitors, allopurinol, mometasone, metformin, simvastatin, levothy

207 -sulfamethoxazole (n = 11), dapsone (n = 4), allopurinol (n = 10), and other drugs (n = 5).

208 infused I.V. with either vehicle (n =11) or allopurinol (n =10).

209 e enrolled and randomly allocated to receive allopurinol (n=3065) or febuxostat (n=3063).

210 e in vivo effects of maternal treatment with allopurinol on fetal cardiovascular function in ovine pr

211 ngful benefits of serum urate reduction with allopurinol on kidney outcomes among patients with type

212 The effects of maternal allopurinol on maternal and fetal cardiovascular functio

213 achieved by a single oral dose of 600 mg of allopurinol on the day of the study.

214 tudy was to evaluate the effect of high-dose allopurinol on vascular oxidative stress (OS) and endoth

215 In both dosing scenarios, allopurinol-only therapy was cost-saving.

216 e content, which was unaffected after either allopurinol or chronic pesticide exposure alone, was sig

217 Patients for whom allopurinol or febuxostat is a suitable initial urate-lo

218 idence suggests that urate-lowering therapy (allopurinol or febuxostat) reduces long-term risk for ac

219 idence of diabetic kidney disease to receive allopurinol or placebo.

220 Disruption of XDH by allopurinol or XDH1 by RNA interference significantly af

221 ity by pharmacologic (N-acetyl-L-cysteine or allopurinol) or molecular (by small interfering RNA) app

222 thine oxidoreductase (XOR) inhibition (i.e., allopurinol) or nitric oxide donors (i.e., S-nitrosoglut

223 , n = 5) or high dose (150 mg kg(-1), n = 9) allopurinol, or high dose allopurinol with fetal NO bloc

224 ent strategies were evaluated: no treatment; allopurinol- or febuxostat-only therapy; allopurinol-feb

225 ial design, we administered the XO inhibitor allopurinol orally to mice that had undergone massive my

226 gnificantly greater for rasburicase than for allopurinol (P = .001) in the overall study population,

227 ebuxostat, and 21 percent of those receiving allopurinol (P<0.001 for the comparison of each febuxost

228 compared with 50 percent in those receiving allopurinol (P=0.08 for 80 mg of febuxostat vs. allopuri

229 ebuxostat, and 64 percent of those receiving allopurinol (P=0.99 for 80 mg of febuxostat vs. allopuri

230 opurinol (P=0.08 for 80 mg of febuxostat vs. allopurinol; P=0.16 for 120 mg of febuxostat vs. allopur

231 opurinol (P=0.99 for 80 mg of febuxostat vs. allopurinol; P=0.23 for 120 mg of febuxostat vs. allopur

232 Aged offspring of hypoxic allopurinol pregnancy compared with aged offspring of un

233 inol use in pregnant patients and suggest an allopurinol pregnancy registry to document drug exposure

234 acid check within 6 months of starting a new allopurinol prescription, and QI 3 = complete blood coun

235 types following radiation exposure and that allopurinol prevented radiation-induced inflammasome act

236 xicity in the PQ+MB model of PD, and/or that allopurinol produces an antioxidant benefit offsetting i

237 in optimally treated CAD patients, high-dose allopurinol profoundly reduces vascular tissue OS and im

238 We ascertained whether high-dose allopurinol prolongs exercise capability in patients wit

239 Allopurinol protected against 6-TG toxicity by acting as

240 /d intravenously days 1-5), rasburicase plus allopurinol (rasburicase 0.20 mg/kg/d days 1 to 3 follow

241 ed OS, and our second aim was to see whether allopurinol really does reduce vascular tissue OS in CAD

242 (Does a Drug Allopurinol Reduce Heart Muscle Mass and Improve Blood V

243 mothers with the xanthine oxidase inhibitor allopurinol reduced placental uric acid levels, prevente

244 Although oral allopurinol reduced serum and striatal urate levels 4-fo

245 s call for further trials to examine whether allopurinol reduces cardiovascular events in patients wi

246 insulin resistance and hypertension, whereas allopurinol reduces serum levels of uric acid and amelio

247 This study sought to ascertain if high-dose allopurinol regresses left ventricular mass (LVM) in pat

248 High-dose allopurinol regresses LVH, reduces LV end-systolic volum

249 Maternal allopurinol rescued maximal arterial relaxation to acety

250 nt new drug treatment with antiepileptics or allopurinol, respectively.

251 newly diagnosed hypertension, treatment with allopurinol resulted in reduction of BP.

252 rmine whether lowering levels of urate using allopurinol results in exacerbated neurotoxicity in a du

253 xpression; in contrast, inhibition of Xdh by allopurinol results in xdhB repression.

254 citrates (RR, 0.25 [CI, 0.14 to 0.44]), and allopurinol (RR, 0.59 [CI, 0.42 to 0.84]) each further r

255 lacebo or control, although the benefit from allopurinol seemed limited to patients with baseline hyp

256 Allopurinol seems to be a useful, inexpensive, well tole

257 ebuxostat sequential therapy; and febuxostat-allopurinol sequential therapy.

258 Compared with placebo, allopurinol significantly improved endothelium-dependent

259 Allopurinol significantly reduced absolute LVM (-2.65 +/

260 Allopurinol significantly reduced LVH (P=0.036), improve

261 Compared to placebo, allopurinol significantly reduced LVM (allopurinol -5.2

262 Allopurinol single therapy is cost-saving compared with

263 joints that was resistant to treatment with allopurinol, steroids, and antiinflammatory drugs.

264 (3-aminomethyl)benzylacetamidine (1400W), or allopurinol, suggesting a role for both inducible nitric

265 ity was elevated in untreated mice after MI; allopurinol suppressed the XO activity to levels compara

266 rum uric acid levels >/=9.5 mg/dL to receive allopurinol (target dose, 600 mg daily) or placebo in a

267 ashout was 40% (95% CI, 0 to 80) higher with allopurinol than with placebo.

268 kidney disease imparts a dose limitation on allopurinol that further impairs the effectiveness of ur

269 Therefore, allopurinol therapy may become useful to reduce CV event

270 Febuxostat is non-inferior to allopurinol therapy with respect to the primary cardiova

271 stly but more effective than dose-escalation allopurinol therapy, with an incremental cost-effectiven

272 lubility of uric acid, and administration of allopurinol to block production of uric acid.

273 herapy with a thiazide diuretic, citrate, or allopurinol to prevent recurrent nephrolithiasis in pati

274 dative stress was profound because high-dose allopurinol totally abolished the oxidative stress that

275 c marker associated with the risk for severe allopurinol toxicity has been reported.

276 denosine during hypoxia which is seen in the allopurinol-treated animals may potentiate adenosine's i

277 s were compared to 5 untreated hypoxic and 6 allopurinol-treated hypoxic animals.

278 vs. 162.8 +/- 38.3 nmol/gm), P = 0.05 in the allopurinol-treated hypoxic group.

279 Survival doubled in the allopurinol-treated mice, whereas cardiac contractile fu

280 ifications to proteins were prevented in the allopurinol-treated mice.

281 ys) were studied: 5 untreated normoxic and 6 allopurinol-treated normoxic controls were compared to 5

282 ng mice with allopurinol and discovered that allopurinol treatment completely blocked caspase-1 activ

283 entical to that seen in normal control mice, allopurinol treatment of these double-KO mice also enhan

284 Following allopurinol treatment, fetal hypoxia was induced by redu

285 n in TH-positive neurons was not affected by allopurinol treatment.

286 dd significantly to the very limited data on allopurinol use in pregnancy.

287 We encourage reporting of all cases of allopurinol use in pregnant patients and suggest an allo

288 When cherry intake was combined with allopurinol use, the risk of gout attacks was 75% lower

289 ients with IHD and LVH, comparing 600 mg/day allopurinol versus placebo therapy for 9 months.

290 casual and ambulatory criteria while taking allopurinol vs 1 participant while taking placebo (P < .

291 and mean 24-hour ambulatory diastolic BP for allopurinol was -4.6 mm Hg (-2.4 to -6.8 mm Hg) vs -0.3

292 ebo, and the mean change in diastolic BP for allopurinol was -5.1 mm Hg (95% CI, -2.5 to -7.8 mm Hg)

293 e in mean 24-hour ambulatory systolic BP for allopurinol was -6.3 mm Hg (95% CI, -3.8 to -8.9 mm Hg)

294 asual BP, the mean change in systolic BP for allopurinol was -6.9 mm Hg (95% confidence interval [CI]

295 Allopurinol was used throughout pregnancy in all patient

296 These effects of maternal allopurinol were restored to control levels during fetal

297 inflammasome activation by sHz is reduced by allopurinol, which is an inhibitor of uric acid synthesi

298 mg kg(-1), n = 9) allopurinol, or high dose allopurinol with fetal NO blockade (n = 6).

299 Addition of potassium supplements and allopurinol with thiazides might be helpful in the manag

300 e dinucleotide phosphate oxidase inhibitor), allopurinol (xanthine oxidase inhibitor), and ACE8/8 cro